Differentiating non-epileptic seizures from epileptic seizures in Glut1 deficiency syndrome.
Journal
Developmental medicine and child neurology
ISSN: 1469-8749
Titre abrégé: Dev Med Child Neurol
Pays: England
ID NLM: 0006761
Informations de publication
Date de publication:
24 Apr 2024
24 Apr 2024
Historique:
revised:
13
03
2024
received:
03
09
2023
accepted:
21
03
2024
medline:
24
4
2024
pubmed:
24
4
2024
entrez:
24
4
2024
Statut:
aheadofprint
Résumé
To investigate the clinical characteristics of non-epileptic seizures due to transient brain dysfunction caused by energy deficiency after prolonged fasting or exercise in individuals with glucose transporter type 1 deficiency syndrome (Glut1DS), and then elucidate further the seizure features to distinguish non-epileptic seizures from epileptic seizures. This retrospective case-control study included 57 non-epileptic seizures and 23 epileptic seizures (control group) in 14 individuals (11 males, three females; aged 5-44 years, median = 20 years) with Glut1DS, all with a heterozygous pathogenic SLC2A1 mutation. Non-epileptic seizures were classified as paroxysmal altered consciousness (n = 8), movement disorders (n = 35) (eye-head movements, ataxia, spasticity, weakness, involuntary movement), dysaesthesia (n = 8), and vomiting (n = 6) at the peak ages at onset of 5 to 10 years. Ketogenic diet therapy was effective in 33 of 43 (77%) non-epileptic seizures. Providing supplementary food before high-impact exercise or during attacks prevented or mitigated non-epileptic seizures in some individuals. Glut1DS-associated non-epileptic seizures are fundamentally situation-related seizures with specific provoking and ameliorating factors. Non-epileptic seizures can be distinguished from epileptic seizures by the absence of complete consciousness loss and rapid postictal recovery despite prolonged seizures. Non-epileptic seizures are not well recognized but require different therapeutic approaches compared to epileptic seizures. Awareness of the differentiation of non-epileptic seizures from epileptic seizures is essential when performing preventive or therapeutic decision-making for acute exacerbation seizures.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Research on Rare and Intractable Diseases, Health and Labour Sciences Research.
ID : 20FC1025
Informations de copyright
© 2024 Mac Keith Press.
Références
Papetti L, Parisi P, Leuzzi V, Nardecchia F, Nicita F, Ursitti F, et al. Metabolic epilepsy: an update. Brain Dev 2013; 35: 827–41.
Gras D, Roze E, Caillet S, Méneret A, Doummar D, Billette de Villemeur T, et al. GLUT1 deficiency syndrome: an update. Rev Neurol (Paris) 2014; 170: 91–9.
Klepper J, Akman C, Armeno M, Auvin S, Cervenka M, Cross HJ, et al. Glut1 Deficiency Syndrome (Glut1DS): State of the art in 2020 and recommendations of the international Glut1DS study group. Epilepsia Open 2020; 5: 354–65.
Ito Y, Takahashi S, Kagitani‐Shimono K, Natsume J, Yanagihara K, Fujii T, et al. Nationwide survey of glucose transporter‐1 deficiency syndrome (GLUT‐1DS) in Japan. Brain Dev 2015; 37: 780–9.
Hauser WA, Beghi E. First seizure definitions and worldwide incidence and mortality. Epilepsia 2008; 49 Suppl 1: 8–12.
Klepper J, Leiendecker B, Eltze C, Heussinger N. Paroxysmal nonepileptic events in Glut1 deficiency. Mov Disord Clin Pract 2016; 3: 607–10.
De Vivo DC, Trifiletti RR, Jacobson RI, Ronen GM, Behmand RA, Harik SI. Defective glucose transport across the blood‐brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. N Engl J Med 1991; 325: 703–9.
Ichord RN. Perinatal metabolic encephalopathies. In: Swaiman KF, Ashwal S, Ferriero DM, Schor NF, editors. Swaiman's Pediatric Neurology. 5th edition. Principles and Practice. China: Elsevier Saunders, 2012: 100–19.
Pons R, Collins A, Rotstein M, Engelstad K, De Vivo DC. The spectrum of movement disorders in Glut‐1 deficiency. Mov Disord 2010; 25: 275–81.
Anheim M, Maillart E, Vuillaumier‐Barrot S, Flamand‐Rouvière C, Pineau F, Ewenczyk C, et al. Excellent response to acetazolamide in a case of paroxysmal dyskinesias due to GLUT1‐deficiency. J Neurol 2011; 258: 316–7.
Chambon R, Vuillaumier‐Barrot S, Seta N, Wagner S, Sarret C. Partial effectiveness of acetazolamide in a mild form of GLUT1 deficiency: a pediatric observation. Mov Disord 2013; 28: 1749–51.
Michel V, Riant F, Tournier‐Lasserve E, Guehl D, Lagueny A, Bioulac B, et al. Long‐term improvement of paroxysmal dystonic choreathetosis with acetazolamide. J Neurol 2006; 253: 1362–4.
Málaga I, Avila A, Primeaux S, Park JY, Pascual JM. A concise study of acetazolamide in glucose transporter type 1 deficiency (G1D) epilepsy. Epilepsia 2023; 64: e184–9.